New phase I/II clinical trial : everolimus and paclitaxel albumin-stabilized nanoparticle in treating breast cancer

The Cancer Institute of New Jersey and the National Cancer Institute launched in July 2009 a new phase I/II clinical trial involving a nanoparticle formulation, which is now registered in the database under reference NCT00934895. According to this page, “this phase I/II trial is studying the side effects and best dose of everolimus when given together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well it works in treating women with locally advanced or metastatic breast cancer.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: